Moleculin Biotech, a Houston-based clinical-stage pharmaceutical company, focuses on developing treatments for tumors and viruses with three core technologies and six drug candidates. Established in 2016, it employs 18 people and has candidates showing human activity in trials.
Moleculin Biotech (MBRX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Moleculin Biotech's actual EPS was -$0.69, missing the estimate of -$0.57 per share, resulting in a -21.89% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
